NCT03544996

Brief Summary

An Early Feasibility Study of a device formulation to deliver human insulin across intact skin

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Sep 2017

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 9, 2017

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 4, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 4, 2018

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

May 22, 2018

Completed
13 days until next milestone

First Posted

Study publicly available on registry

June 4, 2018

Completed
Last Updated

June 6, 2018

Status Verified

May 1, 2018

Enrollment Period

5 months

First QC Date

May 22, 2018

Last Update Submit

June 2, 2018

Conditions

Keywords

Insulin, needle-less, transdermal

Outcome Measures

Primary Outcomes (1)

  • Insulin response

    Measurement of down modulation of serum glucose as measured by a standard blood glucose meter not otherwise attributable to injected insulin

    8-24 hours

Study Arms (1)

TD Insulin Pilot

Test of novel transdermal insulin (TD Insulin) formulations

Combination Product: TD Insulin

Interventions

TD InsulinCOMBINATION_PRODUCT

Human Insulin USP formulated in a solution capable of transdermal delivery.

TD Insulin Pilot

Eligibility Criteria

Age60 Years - 61 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

Single patient, brittle T1D patient

You may qualify if:

  • Brittle T1D patient with poor insulin sensitivity requiring more than 3,000 IUs on insulin a day

You may not qualify if:

  • High insulin sensitivity
  • well managed serum glucose

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Langford Research Institute

Palm Beach Gardens, Florida, 33410, United States

Location

MeSH Terms

Conditions

Insulin Resistance

Condition Hierarchy (Ancestors)

HyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • William D Kirsh, D.O.

    Sentry Data Systems

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 22, 2018

First Posted

June 4, 2018

Study Start

September 9, 2017

Primary Completion

February 4, 2018

Study Completion

February 4, 2018

Last Updated

June 6, 2018

Record last verified: 2018-05

Locations